FDA Grants Priority Review To Genentech's Enspryng For MOGAD, Phase III METEOROID Study Showed 68% Reduction In Relapse Risk Versus Placebo
If approved, Enspryng would be the first and only disease-modifying therapy for MOGAD (myelin oligodendrocyte glycoprotein antibody-associated disease)Filing acceptance is based on the Phase III METEOROID study showing
Genentech's new medicine for a rare nerve disease got fast-track approval from regulators because it worked better than placebo in testing. When a company gets this green light for a first-of-its-kind treatment, it shows doctors and patients are waiting for it.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.